Multiple electrode aggregometry and ADP-receptors. Adding ASA (acetylsalicylic acid) reagent to a blood sample reduces the aggregation responses in ASPItest and COLtest. ASA irreversibly inhibits COX1 in platelets, thereby inhibiting the production of TXA2. The ASA Reagent is used as a quality control in the platelet function testing with Multiplate, allowing the assessment of abnormal platelet responses in ASPItest and COLtest. This reagent is used as a quality control in Multiplate platelet function testing. The GPIIb/IIIa antagonist blocks the binding of fibrinogen to the GPIIb/IIIa receptors, preventing the formation of platelet-fibrinogen bonds and resulting in significantly reduced platelet aggregation in response to all
Cob(I)yrinic acid a,c-diamide adenosyltransferase Cob(I)yrinic acid a,c-diamide adenosyltransferase In molecular biology, cob(I)yrinic acid a,c-diamide adenosyltransferase (also known as ATP:cob(I)alamin adenosyltransferase or ATP:corrinoid adenosyltransferase) is an enzyme which catalyses the conversion of cobalamin (vitamin B12) into one of its coenzyme forms, adenosylcobalamin (coenzyme B12, AdoCbl). Adenosylcobalamin is required as a cofactor for the activity of certain enzymes. AdoCbl contains an adenosyl moiety liganded to the cobalt ion of cobalamin via a covalent Co-C bond. ATP:cob(I)alamin adenosyltransferases are classed into three groups: CobA-type, EutT-type and PduO-type. Each of the three enzyme types appears to be specialised for particular AdoCbl-dependent enzymes or for the de novo synthesis